Advertisement

PentaVision

Eyecare Business

Article

Building the Myopia Toolbox

The myopia management landscape in the United States may be developing more slowly than other global markets, but the first wave of FDA-approved technologies is shaping the standard of care and redefining how practitioners approach progressive myopia.

By: Veronica Daub
Eyecare Business June 30, 2026

Clinical Report: Building the Myopia Toolbox

Background

Myopia is increasingly recognized as a chronic, progressive condition that can significantly impact long-term eye health. The development of effective management strategies is crucial, especially as the prevalence of myopia continues to rise globally. The introduction of FDA-approved technologies marks a notable advancement in the standard of care for managing pediatric myopia.

Data Highlights

TechnologyTypeFDA Approval YearAge GroupMyopia Progression Reduction
CooperVision MiSight 1 dayContact Lens20198-12 years59% over 3 years
Essilor StellestSpectacle Lens20256-12 yearsSlowed progression (specific % not provided)
Acuvue Abiliti OvernightOrthokeratology Lens2021Not specified0.28 mm reduction over 2 years

Key Findings

  • CooperVision MiSight 1 day is the first FDA-approved soft contact lens to slow pediatric myopia progression.
  • Essilor Stellest lenses utilize H.A.L.T. technology to create myopic defocus and are the first spectacle lenses approved for myopia management.
  • Acuvue Abiliti Overnight lenses are designed to reshape the cornea and manage myopia progression while providing clear daytime vision.
  • Clinical studies show MiSight lenses reduce myopia progression by approximately 59% compared to single-vision lenses.
  • Essilor Stellest lenses have demonstrated efficacy in slowing myopia progression in children aged 6 to 12.
  • Acuvue Abiliti lenses reduced axial elongation by an average of 0.28 mm over two years.

Clinical Implications

These FDA-approved technologies provide practitioners with options for managing pediatric myopia. They correct vision and address the underlying progression of myopia.

Conclusion

The emergence of these myopia management tools represents a step forward in addressing the public health challenge of myopia in children.

Related Resources & Content

  1. Eyecare Business, Building the Myopia Toolbox, 2023 -- Overview of FDA-approved myopia management technologies
  2. Contact Lens Spectrum, MASTERING MYOPIA, 2023 -- Strategies for enhancing myopia management
  3. Optometric Management, Why Myopia Management Fails in Private Practice and How to Fix It, 2026 -- Insights on myopia management challenges
  4. IMI—Interventions for Controlling Myopia Onset and Progression 2025 - PMC, 2025 -- Evidence-based guidelines for myopia management
  5. optometric management — The Myopia Control Kit
  6. Contact Lens Spectrum — Mastering Myopia: 
    Break Through With Myopia Management
  7. FDA approval letter for MiSight 1 Day
  8. Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children
  9. IMI—Interventions for Controlling Myopia Onset and Progression 2025 - PMC